# Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Source: https://onco.cc/trials/nct05804045/  
OnCo record `nct05804045` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pimicotinib(ABSK021) in tenosynovial giant cell tumour, run by Abbisko Therapeutics Co, Ltd, active and no longer recruiting.

## Summary

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) is a phase 3 interventional study registered as NCT05804045 by Abbisko Therapeutics Co, Ltd, with 94 participants enrolled, started 2023-04-27 and due to reach its primary completion in 2024-09-23. Interventions recorded: Pimicotinib(ABSK021) and Placebo. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05804045
- Phase: 3
- Setting: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT05804045: https://clinicaltrials.gov/study/NCT05804045

## Connected records

- cancers: [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct05804045.json